According to data provided by Zacks Research, Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has a consensus target price of $17.444 on the stock. Out of the polled analysts providing targets, the high is currently $45, while the low is resting at $9. Analyst price targets may vary depending on the individual method used to calculate the estimate.
Turning to earnings, analysts are expecting Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to post a current quarter EPS of $0.96. This consensus number is compiled by Zacks Research. For the period ending on 2016-12-31, the company reported EPS for the quarter of $1.26. The resulting surprise factor from the difference between the reported number and the consensus estimate going into earnings was 1.61%. After a company reports earnings, the stock may see increased activity. The next earnings report date is scheduled on or near 2017-05-09.
In terms of analyst ratings, Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has a current ABR of 3.2. This average broker recommendation is given by Zacks using a scale from 1 to 5. According to this scale, a rating of 1 or 2 would indicate a Buy, and a rating of 4 or 5 would signify a Sell recommendation. A 3 would indicate a Hold on the stock.
In the most recent session, Intuitive Surgical, Inc. (NASDAQ:ISRG) shares have traded -0.08%. Following the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent review, the stock has been noted $63.68 away from the 50-day moving average of $772.19 and $136.93 away from the 200-day moving average of $698.94. From a different angle, the stock has been recently recorded -1.02% off of the 52-week high of 844.46 and +36.87% removed from the 52-week low of 610.71.
Currently, Intuitive Surgical, Inc. has a price to earnings ratio of 42.14. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may show that the company is overvalued. A PEG Ratio near one may be viewed as fair value. The stock currently has a PEG Ratio of 3.20.
Price Target Update
Analysts polled by Thomson Reuters have set a consensus target price of $842.85 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets. This is a near-term estimation for the next 12-18 months.